Kornimate/medical-research-clean huggingface dataset:
efficacy of amplification with hearing aids for tinnitus relief

Conditions: Tinnitus, Subjective; Hearing Impairment

Summary: this study evaluates the treatment efficacy of tinnitus in people with mild hearing loss. one-third of participants will use hearing aid, one-third of participants will use customized music, while the other one-third participants will receive no treatment (waiting list control).

acoustic stimulation could induce plastic changes in the auditory cortex, and tinnitus mechanisms have been viewed as a negative consequence of neural plasticity in the central nervous system after peripheral aggression. cortical changes (neural activity in the deafferented cortical area was reduced but the adjacent frequencies of the hearing loss region activated more extensive cortical areas) occur after sensorineural hearing loss, while exposure to an acoustically enriched environment or using hearing aids may minimize or reverse the plastic tonotopic map changes in the auditory cortex. the use of hearing aids in tinnitus management for people with significant hearing loss will always be associated with an improvement in hearing handicap and quality of life, and that complicates the interpretation of how much hearing aids specifically affect tinnitus. thus studies on tinnitus patients with mild hearing loss could be illuminating, and this population will be targeted in the present study.

Eligibility criteria:
inclusion criteria: * 18 years old or above * can provide written informed consent * have a diagnosis of subjective tinnitus, i.e., the tinnitus can only be heard by the patient and there is no acoustic source * a tinnitus duration of more than one year * have pure-tone average between 20 and 40 db hl * have bilateral symmetrical hearing loss (i.e. difference less than 15 db) * have at least a medium level of distress caused by tinnitus as indicated with total scores above 30 on the tq-ch * are committed to complete the 12-month follow-up exclusion criteria: * objective tinnitus, i.e. tinnitus produced by an internal acoustic source activating the cochlea and can be heard by another person * received other forms of tinnitus treatments within three months before the baseline assessment session * any history suggestive of psychiatric illness * psychological distress or depression as indicated with total scores at or above 15 on the cantonese hads * current hearing aid users * inability to complete the study as revealed by the medical reports

Keywords: tinnitus hearing loss amplification sound therapy
study of the effect of eicosanoids on contractile activity of pregnant human myometrium in pathological situation

Conditions: Obstetric Labor Complications; Prolonged Pregnancy

Summary: recent studies show that eet and 20-hete have important biological effects, particularly in the vascular system. the investigators studied the effect of eicosanoids on the gravid rat uterus. the results suggest that 20-hete had an tocolytics effect on gravid uterus. in the previous study, we demonstrated that the enzymes of the pathway of eet were present in human uterine tissues. moreover, the addition of an inhibitor of degradation of eet had an tocolytic effect on the human myometrium, as the exogenous addition of 8.9, 14,15-eet and 20-hete. objectives: primary objective: to compare the balance of different metabolic pathways of arachidonic acid (aa) of the pregnant human myometrium in pathological situations (preterm labor, uterine atony, prolonged pregnancy). specific objectives: i) to study the effect of derived from the aa on in vitro contractile activity of normal and pathological uterine tissues, and ii) detect and quantify the different sub-products of metabolism of aa in the uterine tissues (myometrium, fetal membranes and placenta). the management of uterine contraction is in the heart of modern obstetrics year, yet the progress made in other specialties, based on the study of smooth muscle have not yet been transposed in obstetrics. a better understanding of systems for regulating the contraction is important in terms of 1) new physiological knowledge, but it could also be the source of 2) modification of strategies to take care of premature delivery (new tocolytic), or 3) improving the efficiency of uterine muscle during delivery or 4) for treatment of patients with prolonged pregnancy.

it is a clinical study with a slope fundamental aims to examine the metabolic pathways of aa of human myometrium and their functional roles according to their clinical profile divided into three contractile pathological situations - threat of premature delivery, dynamic dystocia, prolonged pregnancy - and two groups of patients at term: a group before work and group work. the sampling method. after birth, a biopsy will be perform from the lower segment of the uterus. after caesarean sections of membrane and placenta are collected. the substances studied during isometric tension tests are part of the three degradation pathways of the aa. 1. new eicosanoids in cumulative dose (8,9-eet, 11,12-eet, 14,15-eet, 20-hete), and in combination 2. enzyme inhibitors of the eicosanoids pathway (auda, ms-ppoh, ddms), and the cox and lox pathways (indomethacin), alone or in combination.

Eligibility criteria:
inclusion criteria: * all women who will have a c-section exclusion criteria: * induction of labor, * child with malformation, * birth weight less than 2500 grams or greater than 4500g

Keywords: contractile activity eicosanoids pregnant women obstetrics complications
study evaluating moa-728 oral for the treatment of oibd in subjects with chronic non-malignant pain

Conditions: Constipation

Summary: the primary purpose of this study is to evaluate the safety and dose-response relationship of n-methylnaltrexone bromide (moa-728) by observing spontaneous bowel movements in subjects administered moa-728 who have chronic pain that is not due to cancer, and who have opioid-induced bowel dysfunction (oibd).


Eligibility criteria:
inclusion criteria: * adult outpatients with opioid-induced bowel dysfunction and chronic pain, which is not due to malignant cancer. * taking oral, transdermal, intravenous, or subcutaneous opioids. * willingness to discontinue all pre-study laxative therapy and use only study permitted rescue laxatives. exclusion criteria: * history of chronic constipation before the initiation of opioid therapy. * other gi disorders known to affect bowel transit. * women who are pregnant, breast feeding, or plan to become pregnant.
eat well produce benefit for diabetes and food insecurity

Conditions: Diabetes Mellitus; Food Insecurity

Summary: the goal of this clinical trial is to assess the impact of participation in eat well for diabetes patients who are at risk of food insecurity. the main questions it aims to answer are: * whether there is a difference in haemoglobin (hb) a1c measurements and emergency department (ed) utilization between the eat well and control groups up to 18 months post-program completion. * whether there are differences in cardiometabolic health-related outcomes for eat well participants. participants in the program will receive gift/debit cards for fruits and vegetables and educational nutrition materials. researchers will compare eat well participants with those only receiving educational materials to see if there are differences in cardiometabolic health outcomes.

this pragmatic trial aims to assess the impact of eat well participation for diabetes patients at risk of food insecurity. eligible patients will receive gift/debit cards for the special supplemental nutrition program for women, infants, and children (wic)-approved fruits and vegetables and be assigned to either receive the card for up to 12 months or not. random assignment will occur using a 2 to 1 treatment to control allocation ratio. both treatment and control groups will receive curated diabetes educational materials. the study will assess the impact of the intervention on clinical factors such as glycemic control, weight, bmi, lipids, medication adherence, medication number, blood pressure, and utilization up to 18 months pre, during, and post program enrollment using data from clinical visits. the primary analysis of interest will be differences in hba1c measurements and ed visits between the eat well and control groups at 12 months of program participation, with further evaluation of differences at 12 months post-program completion.

Eligibility criteria:
inclusion criteria: * be active in the duke diabetes registry in the past 12 months and * have had at least one outpatient a1c measurement and * are at risk for food insecurity as defined by one of the following: 1. answered often true or sometimes true on one or both of the food insecurity questions as part of the electronic health record social history section (maestro care/ epic of verona wi) or 2. answered hard or very hard to the financial stress question as part of the electronic health record social history section (maestro care/ epic of verona wi) or 3. has medicaid as insurance payer or 4. lives in area deprivation index (adi) zip code of 7th decile or harder exclusion criteria: * none
endoscopic sleeve gastroplasty for obesity and microbiota randomized trial

Conditions: Obesity; Endoscopic Sleeve Gastroplasty; Gastric Motility; Gastric Hormones; Microbiota; Quality of Life

Summary: this is an interventional, open-label, randomized (2:1), standard medical therapy-controlled trial. subjects in the standard therapy group will be given the opportunity to undergo the active endoscopic treatment after 6 months of follow up (open label extension) if they will not achieve an adequate result on body weight. all patients will be followed until the planned end of the study after 36 months from the esg procedure. to study the effects of endoscopic gastroplasty on weight, metabolic risk factors, quality of life, satiety, gastrointestinal motility and gut microbiota compared to standard medical treatment control group. primary endpoint: - total body weight loss (%) secondary endpoints: * metabolic risk factors (e.g. lipid profile) and anthropometric measurements (e.g hip and waist circumference) * body composition * quality of life * gastroesophageal reflux disease * non-alcoholic fatty liver disease (nafld) * non- alcoholic-steato-hepatitis (nash) * satiety * gut microbiota exploratory endpoints: * gut hormones e.g. glucagon-like peptide 1, pyy and ghrelin * gastrointestinal motility


Eligibility criteria:
inclusion criteria: the participants have to fulfill the following criteria for participating in the study: * age 20 to 65 years * bmi between 30 to 45 kg/m2 * willingness to participate in the study and ability to comply and understand the study protocol exclusion criteria: active gastric ulcer during the last 6 months * organic or motility disorder of the stomach and / or esophagus * anticoagulant treatment * previous bariatric surgery or any other type of surgery of the esophagus, stomach and duodenum * ongoing or active malignancy during the last 5 years * myocardial infarction during the past 6 months or/and heart failure class iii or iv according to the new york heart association's classification * drug or alcohol abuse * bulimic or binge eating pattern * continuous glucocorticoid or anti-inflammatory treatment * uncontrolled thyroid disease * pregnancy, breastfeeding * psychiatric or cooperative problems or low compliance that is a contraindication from participating in the study * hiatal hernia \> 5 cm * currently participating in other study * any health issue that might put the patient at risk if the treatment is performed, judged by the investigator
magnesium sulphate and sevoflurane induced emergence agitation in children

Conditions: Emergence Delirium; Postopertive Delirium; Emergence Agitation in Children

Summary: rationale: pediatric adenotonsillectomy is a common procedure of brief performed on a day-case basis, in which rapid recovery with safe airway after extubation is crucial. sevoflurane is considered the inhaled anesthetic of choice in such procedures, however it has been reported that emergence agitation (ea) is a frequent complication in 30-80% of children receiving sevoflurane general anesthesia. the possible effect of magnesium sulphate on decreasing the incidence of ea in children was not adequately investigated. objective: to assess the possible effects of intraoperative intravenous magnesium sulphate (mgso4) infusion on the incidence of sevoflurane-induced ea in children undergoing adenotonsillectomy. study population and sample size: children 4-7 years, asa physical status i or ii, undergoing adenotonsillectomy under sevoflurane general anesthesia. 64 patients (32/group) is required to detect a significance difference of 40% in the incidence of agitation between two groups, with a power of 80% and alpha error of 5%. study design: a double blind, randomized, placebo controlled study. method: in the placebo group, a normal saline bolus dose 0.3ml/kg will be iv infused followed by a continuous infusion of 0.1 ml/kg/h. in the mgso4 group, a mgso4 bolus dose 0.3ml/kg will be iv infused followed by a continuous infusion of 0.1 ml/kg/h. infusion terminated by the end of surgery. post operative emergence agitation will be assessed by using the pediatric anesthesia emergence delirium scale. possible risks: drug side effects such as facial warmth, flushing, dry mouth, and malaise. outcome parameters: the primary outcome: incidence of sevoflurane-induced ea measured using the pediatric anesthesia emergence delirium (pead). secondary outcome: postoperative pain and rescue analgesic requirements, perioperative hemodynamics, durations of recovery, postoperative complications statistical analysis plan: student's t-test or mann whitney-u and chi square or fisher's exact tests will be used as appropriate. the possible relationship between ea and pain scores will be evaluated with the use of spearman's rank correlation coefficient time plan: 6-9 months.


Eligibility criteria:
inclusion criteria: children 4-7 years, asa physical status i or ii, undergoing adenotonsillectomy will be included in the study. exclusion criteria: * the study will exclude children with behavioral changes, physical developmental delay and children on treatment with sedative or anticonvulsant. also children with pre-existing renal disease or cardiovascular diseases will be excluded.

Keywords: emergence agitation in children sevoflurane general anesthesia magnesium sulphate
hydronephrosis on ultrasound with ct finding in patients with renal colic

Conditions: Hydronephrosis; Renal Colic

Summary: the purpose of this study is to determine the overall sensitivity and specificity of hydronephrosis on point-of-care bedside ultrasound to identify hydronephrosis as compared to hydronephrosis found by ct.


Eligibility criteria:
inclusion criteria: * emergency department patients 18 yrs or older with suspected renal colic in whom the clinician intends to obtain a ct scan to diagnose kidney stone. * informed consent will be required prior to enrollment in the study. exclusion criteria: * known renal disease (any esrd, transplant, pckd), dementia, trauma, language barrier, incarcerated patients, and patients who do not undergo ct.

Keywords: hydronephrosis ct poc us
telbivudine versus the combination of telbivudine and valtorcitabine in patients with chronic hepatitis b

Conditions: Hepatitis B

Summary: this study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis b.


Eligibility criteria:
inclusion criteria: * clinical history compatible with compensated chronic hepatitis b other protocol-defined inclusion criteria may apply. exclusion criteria: * patient is pregnant or breastfeeding * patient is co-infected with hepatitis c virus, hepatitis d virus or hiv * patient has previously received lamivudine, adefovir dipivoxil or an investigational anti-hepatitis b virus (hbv) nucleoside or nucleotide at anytime. other protocol-defined exclusion criteria may apply.
nationwide observation study to evaluate the efficacy and tolerance of the adjustable medical device remeex® in the treatment of male stress urinary incontinence

Conditions: Urinary Incontinence,Stress

Summary: we wish to set up a multicentric prospective observational study across france to collate data on the efficacy and tolerance of the male remeex® device in patients with moderate stress urinary incontinence following radical prostatectomy. patient satisfaction, improvement in quality of life, side effects and complications will also be studied, as will the ease of use of the device from the point of view of the surgeon. a long-term follow-up of 5 years will be conducted.


Eligibility criteria:
inclusion criteria: * the patient has been informed about the study * the patient is at least 18 years old * patient suffering from moderate stress incontinence (pure or predominant) following radical prostatectomy surgery, for at least 12 months, unresolved after of pelvic floor reeducation * patient scheduled for remeex® implant exclusion criteria: * it proves impossible to give the patient clear information * patient refuses to participate * life expectancy of the patient estimated to be less than the 5 year follow-up * impossible to contact patient after hospitalization * radiotherapy of less than 6 month * patient unable to fill in questionnaire * incapably of performing pad test at 24 hours * recurrent symptomatic prostate cancer * mixed incontinence with urgency incontinence * bladder outlet obstruction: stenosis of the vesico-urethral anastomosis or untreated urethral stricture. * post void residual \>100ml * other cancer under treatment or progressing * kidney injury, hepatocellular insufficiency * auto-immune disease * neurological-origin urinary incontinence (stroke, ms, parkinson's) * incontinence arising from surgery other than prostatectomy * recurrent gross hematuria * recurrent urinary infection * bladder stones
nsaid use after robotic partial nephrectomy

Conditions: Kidney Cancer; Renal Cancer; Renal Neoplasm

Summary: the purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (nsaids) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.


Eligibility criteria:
inclusion criteria: * patients undergoing uncomplicated robotic assisted laparoscopic partial nephrectomy for renal mass at the university of miami hospital and network sites (deerfield beach, plantation, lennar (coral gables), and kendal). * age 18-99. * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * allergy to nsaids * myocardial infarction or unstable angina within 12 months. * any history of coronary artery bypass graft surgery. * history or active peptic ulcer disease, gastrointestinal (gi) bleeding, gi perforation. history of bleeding disorder. glomerular filtration rate (gfr) \< 60 ml/min/1.73m2 (modification of diet in renal disease (mdrd) equation). * taking any anti-platelet or anti-coagulation medications concurrently (e.g. warfarin, aspirin, clopidogrel, rivaroxaban etc.) * chronic opioid use (use within 12 weeks) or history of opioid use disorder. * solitary kidney. * pregnancy. * inability to give informed consent or unable to meet requirement of the study for any reason.

Keywords: non-steroidal anti-inflammatory drugs (nsaids)
pilot test of a cultural intervention to enhance alaska native students' behavioral health

Conditions: Depression; Anxiety; Suicidal Ideation; Substance Use

Summary: this project aims to enhance an university students' behavioral health by supporting their cultural identity development. while the connection between cultural identity and behavioral health is becoming clearer, comparably less research has explored methods of enhancing identity development. consequently, the investigators will pilot a cultural identity development program for an students at the university of alaska anchorage (uaa). this intervention is based on extant scientific literature, local findings from focus group with an students, and traditional wisdom from an elders. the eight-week elder-facilitated program incorporates storytelling, experiential learning, connection, exploration, and sharing of identity, cultural strengths, life paths, and rootedness in who they are in order to remain grounded when they face changes and challenges. approximately 40 to 50 an university students will be recruited for the intervention. participants will be randomized, with half the participants receiving the intervention in the fall 2020 semester and half the students receiving the intervention in the spring 2021 semester. we hypothesize that engaging in this intervention will strengthen an students' cultural identities, strengths, and sense of community; improve their behavioral health, as evidenced in higher self-reported wellbeing, and lower substance use, depression, anxiety, and suicidal ideation symptoms; and support their academic persistence and achievement. outcomes will be tested via mixed design analyses of covariance. moreover, program feasibility will be examined through a process evaluation, which will entail thematic analyses of six focus groups with program participants (n=40-50) and with the elders who facilitated the program (n=5).


Eligibility criteria:
inclusion criteria: * self-identify as alaska native, * are registered as an undergraduate student at uaa, * are at least 18 years old, * speak english exclusion criteria: -

Keywords: cultural identity sense of community wellbeing alaska native
searching for the liver cancer-related biomarkers

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) has been the leading cause of cancer death in taiwan. about 6000-8000 people died of this cancer every year in taiwan. though regular sonographic examination can early detect small hcc and there are many therapeutic modalities for hcc, the therapeutic results remains unsatisfactory. though alpha-fetoprotein (afp) and des-γ-carboxy prothrombin (dcp) are used as the tumor markers for diagnosis of hccs, these two markers are not good enough for the early detection of small hccs. to improve the survival, further investigations of the early diagnostic markers are still needed. in this current project, we applied the proteomic method to identify the hcc biomarkers.

cell lines hep3b and huh7 hcc cell lines will be cultured in (dulbecco's modified eagle medium) dmem containing 10% fetal calf serum and incubated at 37 c in 5% co2 incubator. the rationale of using hcc cell line instead of clinical hcc samples is that hcc tissues are heterogeneous and might contain some non-hcc cells. the cell will be harvested when cells reach 95% confluence. sera collection 20 ml of venous 20 ml of venous blood was collected from 20 hbv-related hcc and 20 hcv-related hcc patients before treatment. the venous blood was allowed to clot, centrifuged at 800 g for 5 min, and serum was aliquoted and stored at -80 0c. control sera were obtained from 20 hbv carriers without hcc, 20 chronic hepatitis c patients without hcc, and 10 normal subjects without liver diseases. two-dimensional gel electrophoresis using patients' sera for immunoblotting will be done. spots of interest will be identified by delayed extraction matrix-assisted laser desorption ionization.

Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma exclusion criteria: * multiple cancers